Literature DB >> 9882029

Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam.

C D Settle1, M H Wilcox, W N Fawley, O J Corrado, P M Hawkey.   

Abstract

BACKGROUND: Rates of Clostridium difficile diarrhoea have recently been rising, with the elderly being at highest risk. AIM: To compare the incidence of C. difficile colonization and diarrhoea in elderly patients treated for presumed infection with either empirical cefotaxime (CTX) or piperacillin-tazobactam (PT).
METHODS: A prospective, ward-based, crossover study was carried out on two well-matched care of the elderly wards at a UK tertiary care hospital, in patients requiring empirical broad-spectrum antibiotic treatment.
RESULTS: There was a highly significant increased incidence of C. difficile colonization (26/34 vs. 3/14, P=0.001) and diarrhoea (18/34 vs. 1/14, P=0.006) in patients who received CTX as opposed to PT. DNA fingerprinting suggested that most infections arose from strains acquired from the hospital environment.
CONCLUSIONS: Elderly patients are significantly less likely to develop C. difficile diarrhoea after treatment with PT than after CTX. The source of C. difficile appears to be predominantly from the ward environment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9882029     DOI: 10.1046/j.1365-2036.1998.00428.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  22 in total

1.  Choosing the right antibiotic. Right drug at right time in right dose saves lives.

Authors:  D Bihari
Journal:  BMJ       Date:  1999-10-02

2.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

3.  Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.

Authors:  Nicole J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Comparative analysis of prevalence, risk factors, and molecular epidemiology of antibiotic-associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus.

Authors:  N J Asha; D Tompkins; M H Wilcox
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection.

Authors:  Sahil Khanna; Emmanuel Montassier; Bradley Schmidt; Robin Patel; Daniel Knights; Darrell S Pardi; Purna Kashyap
Journal:  Aliment Pharmacol Ther       Date:  2016-08-02       Impact factor: 8.171

6.  Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.

Authors:  Michelle M Nerandzic; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

7.  A time-series analysis of clostridium difficile and its seasonal association with influenza.

Authors:  Philip M Polgreen; Ming Yang; Lucas C Bohnett; Joseph E Cavanaugh
Journal:  Infect Control Hosp Epidemiol       Date:  2010-04       Impact factor: 3.254

8.  Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.

Authors:  Robin L P Jump; Yuejin Li; Michael J Pultz; Georgios Kypriotakis; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

Review 9.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Investigation of toxin gene diversity and antimicrobial resistance of Clostridium difficile strains.

Authors:  Shanshan Zhu; Huaping Zhang; Xinsheng Zhang; Chao Wang; Guangming Fan; Weifeng Zhang; Gang Sun; Huihong Chen; Liming Zhang; Zhaoyun Li
Journal:  Biomed Rep       Date:  2014-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.